FindTrial
Sign In

ALLO-501A

DRUG4 trials

Sponsors

Allogene Therapeutics Inc., Allogene Therapeutics

Conditions

Large B-Cell Lymphoma (LBCL)Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaRelapsed/Refractory Large B Cell Lymphoma

Phase 1

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Active, not recruitingNCT04416984
Allogene TherapeuticsRelapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Start: 2020-05-21End: 2029-05-01Target: 160Updated: 2026-03-04

Phase 2

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
TerminatedNCT05714345
Allogene TherapeuticsRelapsed/Refractory Large B Cell Lymphoma
Start: 2023-11-01End: 2024-10-28Updated: 2026-03-02
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
CompletedCTIS2022-501927-25-00
Allogene Therapeutics Inc.Large B-Cell Lymphoma (LBCL)
Start: 2023-09-29End: 2024-01-12Target: 35Updated: 2024-01-15
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy
CompletedCTIS2023-503830-27-00
Allogene Therapeutics Inc.Large B-Cell Lymphoma (LBCL)
Start: 2023-10-17End: 2024-10-28Target: 35Updated: 2024-01-29

Related Papers

Clinical Response after Allogeneic CAR T Cell Therapy Is Linked to Expansion of Identical CD8+ Effector-like T Cell Clones
Blood2024-11-05
ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas
Blood2023-11-0213 citations
Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-Cell Lymphoma
Blood2023-11-023 citations
P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
HemaSphere2023-08-014 citations
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
Journal of Clinical Oncology2023-06-0116 citations
DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (<i>R</i>/<i>R</i> LBCL)
Hematological Oncology2023-06-014 citations
ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing
Blood2021-11-0543 citations
First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.
Journal of Clinical Oncology2021-05-2024 citations